Maipl Therapeutics, Inc.: Funding, Investors & Team (Oct 2026)
Maipl Therapeutics is developing radically different, first-in-class medicines to treat endometriosis and other diseases. Our first drug candidate, MA-7107, is a potent and highly selective inhibitor of prostaglandin F2α signaling that has virtually no impact on other essential prostaglandin functions.
Maipl Therapeutics, Inc. has raised $140k across 1 funding round on record, the most recent a Pre-Seed of $140k announced in Dec 2023.
That round is below the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Maipl Therapeutics, Inc. Company Profile and Key Stats
Latest funding round on record: Dec 2023.
Maipl Therapeutics, Inc. Funding Rounds
Maipl Therapeutics, Inc. Founders and Leadership Team
No contact details are on record for this team yet.
Maipl Therapeutics, Inc. Funding Compared to Other Biotechnology Startups
Maipl Therapeutics, Inc.'s latest round of $140k is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Maipl Therapeutics, Inc. in Biotechnology and Scarsdale
Companies Similar to Maipl Therapeutics, Inc.
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Maipl Therapeutics, Inc. Funding FAQs
What does Maipl Therapeutics, Inc. do?
Maipl Therapeutics is developing radically different, first-in-class medicines to treat endometriosis and other diseases. Our first drug candidate, MA-7107, is a potent and highly selective inhibitor of prostaglandin F2α signaling that has virtually no impact on other essential prostaglandin functions.
How much funding has Maipl Therapeutics, Inc. raised?
Maipl Therapeutics, Inc. has raised $140k across 1 round on record. The most recent is a Pre-Seed of $140k announced in Dec 2023.
When did Maipl Therapeutics, Inc. last raise funding?
Maipl Therapeutics, Inc.'s most recent funding round on record is a Pre-Seed of $140k, announced in Dec 2023.
Who is the CEO of Maipl Therapeutics, Inc.?
Yong G Yue is listed as CEO at Maipl Therapeutics, Inc..
Where is Maipl Therapeutics, Inc. headquartered?
Maipl Therapeutics, Inc. is based in Scarsdale, New York, United States.
How many employees does Maipl Therapeutics, Inc. have?
Maipl Therapeutics, Inc. is in the 1-10 employee band.
How does Maipl Therapeutics, Inc.'s funding compare to other Biotechnology startups?
Maipl Therapeutics, Inc.'s latest round of $140k is below the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Maipl Therapeutics, Inc. Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Maipl Therapeutics, Inc. is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.